FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2026518081> ?p ?o ?g. }

• W2026518081 endingPage "620" @default.
• W2026518081 startingPage "606" @default.
• W2026518081 abstract "Background: Alendronate, a potent antiresorptive agent, effectively reduces fracture risk. Alendronate increases bone mineral density (BMD) and decreases bone turnover markers to a similar extent in white and Asian people, including Japanese. However, no large trials of this drug have been conducted specifically in the Japanese population. Objective: This study examined the antifracture efficacy of alendronate in Japanese patients. Methods: We conducted a 2-year, multicenter, randomized, double-blind, active-controlled, double-dummy trial of women and men with osteoporosis in Japan, with radiographically diagnosed vertebral fracture being the primary end point. Patients were randomized to receive alendronate 5 mg/d or alfacalcidol 1 gmg/d. Results: A total of 365 patients (349 women, 16 men; mean age, 73 years) were enrolled in the study. At the end of 24 months, spinal BMD was significantly increased versus baseline by a mean of 6.9% in the alendronate-treated group (P < 0.001) and 1.5% in the alfacalcidol-treated group; the median increases in BMD at 24 months versus baseline were 8.3% and 1.4%, respectively. The incidence of vertebral fracture >6 months after randomization (the primary end point) was significantly reduced by 66% (relative risk [RR], 0.34; 95% CI, 0.15–0.74) in the alendronate group (4.3% vs 12.7% incidence). When all fractures during the 24 months were considered, the incidence of multiple (≥2) vertebral fractures also was reduced significantly by 67% (RR, 0.33; 95% CI, 0.11–0.96; 2.4% vs 7.3% incidence). The difference in overall incidence (≥1 vertebral fracture during all 24 months) was not significant (12.2% vs 16.7%), implying that risk reductions (relative to the active control) improved after 6 months. This is consistent with bone biology theory, which predicts that several months are required to refill existing resorption sites and increase bone strength more than the active control. Thus, theory predicts that several months would be required to increase bone strength and reduce fracture risk relative to the active control. This study was limited to Japanese participants, but the findings are consistent with results reported from similar studies among white people. Furthermore, because this was an active-controlled trial, it may have underestimated the antifracture efficacy of alendronate relative to a true placebo. Conclusions: The effectiveness of alendronate in reducing the risk of radiographically defined vertebral fracture in Japanese women and men with osteoporosis is similar to that reported previously in white people. As a consequence, the benefits of alendronate in reducing vertebral and hip fractures can be expected to be substantial and early (beginning at month 6)." @default.
• W2026518081 created "2016-06-24" @default.
• W2026518081 creator A5002476975 @default.
• W2026518081 creator A5014568078 @default.
• W2026518081 creator A5014607154 @default.
• W2026518081 creator A5014678644 @default.
• W2026518081 creator A5031011136 @default.
• W2026518081 creator A5033114776 @default.
• W2026518081 creator A5035456514 @default.
• W2026518081 creator A5049082567 @default.
• W2026518081 creator A5061069906 @default.
• W2026518081 creator A5084212317 @default.
• W2026518081 creator A5088773176 @default.
• W2026518081 date "2002-09-01" @default.
• W2026518081 modified "2023-09-27" @default.
• W2026518081 title "The efficacy of alendronate in reducing the risk for vertebral fracture in japanese patients with osteoporosis: A randomized, double-blind, active-controlled, double-dummy trial" @default.
• W2026518081 cites W1961687835 @default.
• W2026518081 cites W1965761014 @default.
• W2026518081 cites W1970192343 @default.
• W2026518081 cites W1979685329 @default.
• W2026518081 cites W1979792772 @default.
• W2026518081 cites W1984421864 @default.
• W2026518081 cites W1985184665 @default.
• W2026518081 cites W1993932749 @default.
• W2026518081 cites W2003656004 @default.
• W2026518081 cites W2034238658 @default.
• W2026518081 cites W2035282044 @default.
• W2026518081 cites W2036632726 @default.
• W2026518081 cites W2040597184 @default.
• W2026518081 cites W2044178924 @default.
• W2026518081 cites W2053053526 @default.
• W2026518081 cites W2066627369 @default.
• W2026518081 cites W2067586128 @default.
• W2026518081 cites W2068503643 @default.
• W2026518081 cites W2075656679 @default.
• W2026518081 cites W2096967244 @default.
• W2026518081 cites W2112629831 @default.
• W2026518081 cites W2123409116 @default.
• W2026518081 cites W2135241080 @default.
• W2026518081 cites W2151845115 @default.
• W2026518081 cites W2153005915 @default.
• W2026518081 cites W2153009489 @default.
• W2026518081 cites W2158331079 @default.
• W2026518081 cites W2161837912 @default.
• W2026518081 cites W2168326240 @default.
• W2026518081 cites W2321227665 @default.
• W2026518081 cites W4243734756 @default.
• W2026518081 cites W4251329994 @default.
• W2026518081 cites W4254234396 @default.
• W2026518081 cites W79965594 @default.
• W2026518081 doi "https://doi.org/10.1016/s0011-393x(02)80065-0" @default.
• W2026518081 hasPublicationYear "2002" @default.
• W2026518081 type Work @default.
• W2026518081 sameAs 2026518081 @default.
• W2026518081 citedByCount "41" @default.
• W2026518081 countsByYear W20265180812012 @default.
• W2026518081 countsByYear W20265180812013 @default.
• W2026518081 countsByYear W20265180812014 @default.
• W2026518081 countsByYear W20265180812016 @default.
• W2026518081 countsByYear W20265180812018 @default.
• W2026518081 countsByYear W20265180812020 @default.
• W2026518081 crossrefType "journal-article" @default.
• W2026518081 hasAuthorship W2026518081A5002476975 @default.
• W2026518081 hasAuthorship W2026518081A5014568078 @default.
• W2026518081 hasAuthorship W2026518081A5014607154 @default.
• W2026518081 hasAuthorship W2026518081A5014678644 @default.
• W2026518081 hasAuthorship W2026518081A5031011136 @default.
• W2026518081 hasAuthorship W2026518081A5033114776 @default.
• W2026518081 hasAuthorship W2026518081A5035456514 @default.
• W2026518081 hasAuthorship W2026518081A5049082567 @default.
• W2026518081 hasAuthorship W2026518081A5061069906 @default.
• W2026518081 hasAuthorship W2026518081A5084212317 @default.
• W2026518081 hasAuthorship W2026518081A5088773176 @default.
• W2026518081 hasConcept C120665830 @default.
• W2026518081 hasConcept C121332964 @default.
• W2026518081 hasConcept C126322002 @default.
• W2026518081 hasConcept C141071460 @default.
• W2026518081 hasConcept C168563851 @default.
• W2026518081 hasConcept C203092338 @default.
• W2026518081 hasConcept C204243189 @default.
• W2026518081 hasConcept C2776541429 @default.
• W2026518081 hasConcept C2776886416 @default.
• W2026518081 hasConcept C2779126354 @default.
• W2026518081 hasConcept C2779809032 @default.
• W2026518081 hasConcept C2908647359 @default.
• W2026518081 hasConcept C61511704 @default.
• W2026518081 hasConcept C71924100 @default.
• W2026518081 hasConcept C99454951 @default.
• W2026518081 hasConceptScore W2026518081C120665830 @default.
• W2026518081 hasConceptScore W2026518081C121332964 @default.
• W2026518081 hasConceptScore W2026518081C126322002 @default.
• W2026518081 hasConceptScore W2026518081C141071460 @default.
• W2026518081 hasConceptScore W2026518081C168563851 @default.
• W2026518081 hasConceptScore W2026518081C203092338 @default.
• W2026518081 hasConceptScore W2026518081C204243189 @default.
• W2026518081 hasConceptScore W2026518081C2776541429 @default.
• W2026518081 hasConceptScore W2026518081C2776886416 @default.
• W2026518081 hasConceptScore W2026518081C2779126354 @default.

• next